Affimed N.V.

Climate Impact & Sustainability Data (2022, 2023)

Total Carbon Emissions:1160 tCO2e/year (estimate)

Scope 1 Emissions:400 tCO2e/year (estimate)

Scope 3 Emissions:760 tCO2e/year (estimate)

Renewable Energy Share:29% (electricity only)

Total Energy Consumption:3400 MWh/year (estimate)

Water Consumption:7400 m3/year (estimate)

Waste Generated:83 kg/year (hazardous waste estimate)

Launched a new web-based learning management system for all employees.
Made donations totaling €60,000 to various organizations.
Improved ISS’s Corporate Solutions E&S Disclosure QualityScore.
Established a new Procurement Function to improve sourcing decisions and supply chain management.
61.6% of employees were female.

Short-term Goals:

Limited environmental data available for initial report; data based on estimates from prior years.
Limited use of materials, energy, and water due to company focus on research and development rather than manufacturing.

Increased transparency and documentation of environmental impact.
Plans to develop future reporting to improve data collection.
Plans to implement measures to make new Mannheim offices more energy-efficient and environmentally friendly.
Plans to reduce travel-related greenhouse gas emissions through a new sustainable business travel policy and associated tool.
Plans to launch a new procurement policy in 2023 with a focus on environmental sustainability.

Supplier Audits: 32

Frameworks Used: GRI (2021 standards)

Implemented EHS Management System including objective setting, risk assessment, preventive measures, training, and reporting; committed to sensitive travel, reduced electricity use, and promoting working from home to reduce carbon footprint; continuously reducing CO2 emissions and energy consumption, avoiding waste, and increasing use of renewable, recycled, and recyclable materials.
Issued first sustainability report in 2023.

Adopted diversity and inclusion policy for supervisory board, management board, and senior management; aimed to have at least one-third women and one-third men on the supervisory board and management board, and 40% women and 40% men in senior management; fulfilled self-set diversity objectives as of December 31, 2023.
Implemented a Code of Conduct and a Code of Conduct for Business Partners to ensure ethical, legal, and professional standards.

Implemented an Enterprise Risk Management System (ERM) to increase shareholder value, guide employees in risk management, address regulatory requirements, and ensure organizational alignment on risk; implemented a three-lines-of-defense model for risk management; established a comprehensive Information Security Management System (ISMS) in accordance with the VdS 10000 guideline; ISMS re-certified in February 2024.
Management board is responsible for establishing and maintaining adequate internal control over financial reporting; implemented a Disclosure Committee to advise on timely review, publication, and filing of reports; internal control over financial reporting deemed effective as of December 31, 2023.

Corporate restructuring and associated headcount reduction may not result in anticipated savings, could result in higher than expected costs, and could disrupt business.
Drug development is expensive, time-consuming, and uncertain; regulatory approvals are not guaranteed.
Limited experience in conducting and managing clinical studies necessary to obtain regulatory approval.
Potential impacts of war, terrorism, geopolitical uncertainties, and business interruptions could disrupt operations and supply chains.
Significant losses incurred since inception and anticipation of continued losses for the foreseeable future; need for substantial additional funding.
Compliance with Nasdaq’s continued listing requirements.

Implementing a restructuring initiative to transform into a focused clinical organization, directing resources towards advancing clinical programs.
Closely monitoring and adhering to relevant federal and local guidelines on COVID-19 to ensure the safety and health of the global workforce and help limit the spread of COVID-19, while maintaining business continuity.
Pursuing various financing alternatives to meet future cash requirements, including issuance of equity, payments from strategic partners, and loan facilities.
Implementing a 1-for-10 reverse stock split to regain Nasdaq listing compliance.